For millions of Americans and global patients suffering from the debilitating pain of gout, treatment options have long been constrained by safety concerns and limited efficacy.
Now, South Korea’s JW Pharmaceutical is accelerating the commercialization of its novel gout drug candidate, Epaminurad, bringing a 16-year development journey closer to the finish line.
The Seoul-based drugmaker announced plans to seek domestic approval and officially launch Epaminurad by 2027. The drug recently gained vital regulatory momentum after being selected for the Ministry of Food and Drug Safety’s (MFDS) fast-track pilot program for new drug approvals.
Having completed two pre-submission meetings in July, the company is preparing to clear the final hurdles for market entry while actively responding to supplementary data requests.
The push for commercialization is heavily buoyed by recently disclosed multi-national Phase 3 clinical trial results. Conducted across 52 institutions in five Asian countries—South Korea, Taiwan, Thailand, Malaysia, and Singapore—the trial evaluated 612 gout patients to ascertain both efficacy and safety.
While the primary dose met all clinical endpoints, a higher 9mg dose—aimed at severe, high-risk cases—did not achieve non-inferiority against an 80mg dose of Febuxostat. JW Pharmaceutical plans to conduct further patient-specific data analysis to refine its clinical strategy for higher-dose administration in the future.
For investors and healthcare providers, the significance of Epaminurad lies in its potential to address a major unmet medical need. Gout is caused by an accumulation of uric acid crystals in the joints, leading to severe inflammation. Patients typically fall into two categories: those who overproduce uric acid, and those who under-excrete it. The vast majority belong to the latter group.
Current standard treatments like Febuxostat focus primarily on inhibiting the body’s production of uric acid.
While existing uricosurics—drugs that promote uric acid excretion—are available, they have seen limited prescription rates due to ongoing concerns regarding renal and hepatic safety.
Epaminurad operates by safely inhibiting the reabsorption of uric acid in the kidneys, effectively promoting its excretion without the traditional safety trade-offs. The company anticipates this mechanism will significantly broaden treatment options for the under-excretion patient population.
The drug’s development timeline reflects a long-term strategic investment, tracing back to 2010 when pre-clinical work began on “URC102,” a candidate discovered at C&C Research Laboratories, a joint venture between JW Pharmaceutical and Japan’s Chugai Pharmaceutical. Following initial human trials in 2013 and subsequent Phase 2 trials in 2016 and 2021, the company successfully out- licensed the drug’s regional rights for China, Hong Kong, and Macau to Simcere Pharmaceutical Group in 2019.
Looking ahead, JW Pharmaceutical is not limiting its ambitions to the domestic market. Following a successful rollout in South Korea, the company is actively reviewing various commercialization strategies, including global licensing agreements and technological partnerships, to bring Epaminurad to international markets, expanding its footprint into broader territories.
